GlassScriptPhysician profile
Leah Haddad
NPI 1033706890
$2,330.71
in general payments reported to CMS, 2019-2025
38 companies · $68.17 in 2025
The $68.17 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,711 · 2022: $395 · 2023: $66.45 · 2024: $90.57 · 2025: $68.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $269.59 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $236.06 | 2021-2022 | |
| Eisai INC. | $148.74 | 2021-2022 | |
| Janssen Biotech, INC. | $138.82 | 2021-2022 | |
| Incyte Corporation | $119.85 | 2021-2022 | |
| Abbvie INC. | $112.22 | 2021-2025 | |
| Astellas Pharma US INC | $101.79 | 2021 | |
| Karyopharm Therapeutics INC. | $92.76 | 2021-2024 | Xpovio |
| Merck Sharp & Dohme LLC | $91.12 | 2021-2022 | |
| Myovant Sciences INC. | $79.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $70.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.50 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $59.19 | 2021-2023 | Imbruvica, Epkinly |
| Exelixis INC. | $51.74 | 2021 | |
| Lilly USA, LLC | $50.67 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $48.28 | 2021-2022 | |
| Emd Serono, INC. | $42.39 | 2021 | |
| Morphosys, US INC. | $41.96 | 2021 | |
| Pfizer INC. | $38.95 | 2021-2022 | |
| Coherus Oncology, INC. | $38.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.04 | 2021 | |
| Celgene Corporation | $37.93 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.64 | 2021 | |
| Daiichi Sankyo INC. | $35.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.95 | 2021 | |
| Blueprint Medicines Corporation | $30.64 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $28.37 | 2021 | |
| Dendreon Pharmaceuticals LLC | $23.97 | 2021 | |
| Fennec Pharmaceuticals, INC. | $22.66 | 2024 | Pedmark |
| Pharmacosmos Therapeutics INC. | $21.30 | 2022 | |
| Genzyme Corporation | $19.88 | 2023 | |
| Organon LLC | $19.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.35 | 2022 | |
| Glaxosmithkline, LLC. | $14.98 | 2021 | |
| Gilead Sciences, INC. | $13.81 | 2021 | |
| Octapharma USA, INC. | $13.62 | 2021 | |
| Eusa Pharma (US) LLC | $13.58 | 2021 | |
| Dova Pharmaceuticals | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.